Why Is Immunic Stock Falling 5% Following Its Third-Quarter Results?

Immunic Inc. (NASDAQ:IMUX) shares declined 5.44% in US premarket trading on Friday after the biotechnology company reported a wider-than-expected third-quarter loss, reflecting increased operating expenses associated with personnel, clinical development and preparations for a potential regulatory submission.

The company reported a net loss of $42.3 million for the three months ended September 30, 2026, compared with $25.6 million in the corresponding period of 2025.

Immunic also confirmed that its two Phase 3 clinical trials evaluating vidofludimus calcium in relapsing multiple sclerosis remain on schedule to report topline results in December 2026.

How Did Immunic’s Third-Quarter Earnings Compare With Expectations?

Immunic reported a third-quarter net loss of $0.99 per share, compared with analysts’ consensus expectations of a $0.94 loss per share.

The reported loss was $0.05 per share wider than forecast.

The company’s total net loss increased to $42.3 million from $25.6 million in the third quarter of 2025.

However, the loss per share narrowed from $1.32 in the prior-year period to $0.99 in the latest quarter, despite the increase in the total net loss.

The difference between the movements in total net loss and loss per share reflects changes in the number of shares used to calculate per-share earnings.

The results showed higher expenditure as Immunic continued its clinical development activities and preparations associated with potential regulatory filings.

Why Did Immunic’s Operating Expenses Increase?

Immunic reported total operating expenses of $43.4 million during the third quarter, compared with $26.0 million in the corresponding period of 2025.

The increase of $17.4 million was primarily attributed to higher personnel costs and activities related to readiness for a potential New Drug Application (NDA).

Research and development expenses increased to $23.9 million from $20.0 million a year earlier.

The company attributed the rise in research and development spending to additional personnel expenses, drug supply costs and regulatory preparation activities.

General and administrative expenses increased to $19.4 million, compared with $6.0 million in the third quarter of 2025.

The increase in administrative expenditure was primarily associated with an $11.0 million rise in personnel expenses.

Of that amount, approximately $9.7 million related to non-cash stock-based compensation arising from a separation agreement.

The stock compensation expense contributed to the reported quarterly loss but did not represent an equivalent cash payment during the period.

When Will Immunic Report Results From Its Phase 3 Multiple Sclerosis Trials?

Immunic confirmed that topline results from its ENSURE-1 and ENSURE-2 Phase 3 clinical trials remain scheduled for December 2026.

Both studies are evaluating vidofludimus calcium as a potential treatment for relapsing multiple sclerosis.

The trials represent a significant component of the company’s clinical development programme, with their results expected to provide information about the investigational treatment’s performance in patients.

Chief Executive Officer Erik Lundgren commented on the approaching clinical milestone.

“As we approach the top-line data from our Phase 3 ENSURE trials in relapsing multiple sclerosis in December, we believe Immunic is entering one of the most important periods in its history,” Lundgren said.

The December results will provide further evidence for evaluating the treatment’s clinical development prospects.

The timing of the announcement remains subject to the completion of the studies’ data analysis and reporting processes.

What Is Immunic Preparing for Ahead of a Potential Regulatory Submission?

Immunic’s third-quarter expenses included additional spending on activities associated with readiness for a New Drug Application.

An NDA is a regulatory submission through which a pharmaceutical company seeks approval from the US Food and Drug Administration to market a new treatment.

The company’s increased expenditure on regulatory preparation reflects work being undertaken alongside the final stages of its Phase 3 clinical programme.

However, the successful completion of clinical trials and any subsequent regulatory approval remain separate processes.

The results of ENSURE-1 and ENSURE-2 will be relevant to determining the next steps for vidofludimus calcium.

Immunic has not provided a specific NDA submission date in the information accompanying its latest quarterly results.

How Long Does Immunic Expect Its Cash Reserves to Last?

Immunic reported cash and cash equivalents of $132.0 million as of September 30, 2026.

Based on its current operating plans, the company expects these resources to support operations into late 2027.

The cash runway extends beyond the anticipated December 2026 announcement of topline results from the ENSURE-1 and ENSURE-2 trials.

The company’s future cash requirements will depend on its clinical development activities, regulatory preparations and operating expenditure.

Immunic’s increased third-quarter expenses highlight the financial resources being allocated to its development programme ahead of the expected clinical data.

The reported cash position provides a reference point for assessing the company’s ability to fund its planned activities during the coming year.

What Are Investors Watching Next for Immunic?

Immunic’s premarket share price decline followed a quarterly loss that exceeded analysts’ expectations and a year-over-year increase in operating expenses.

Investors will be monitoring the anticipated December 2026 topline results from the ENSURE-1 and ENSURE-2 Phase 3 trials of vidofludimus calcium in relapsing multiple sclerosis.

The clinical findings will be relevant to the company’s subsequent development and regulatory plans.

Further attention will focus on Immunic’s operating expenditure, particularly the costs associated with personnel and potential regulatory submissions.

The company’s cash position of $132.0 million and projected operating runway into late 2027 will also remain important considerations.

The third-quarter results reflected increased spending on clinical and regulatory preparation activities, while the approaching Phase 3 data announcements represent the next scheduled milestones in Immunic’s development programme.

Immunic stock price